Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations

Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–993. https://doi.org/10.18632/oncotarget.12587.

Okayama H, Kohno T, Ishii Y, et al. Identification of gene upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012;72(1):100–11. https://doi.org/10.1158/0008-5472.CAN-11-1403.

Meng H, Guo X, Sun D, et al. Genomic profiling of driver gene mutation in Chinese patients with non-small cell lung cancer. Front Genet. 2019;10:1008. https://doi.org/10.3389/fgene.2019.01008.

Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase IV, open-label, single-arm study. Br J Cancer. 2014;110(1):55–62. https://doi.org/10.1038/bjc.2013.721.

Choi YW, Jeon SY, Jeong GS, et al. EGFR exon 19 deletion is associated with favorable overall survival after first-line gefitinib therapy in advanced non-small cell lung cancer patients. Am J Clin Oncol. 2018;41(4):385–90. https://doi.org/10.1097/COC.0000000000000282.

Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. https://doi.org/10.1056/NEJMoa0810699.

Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. https://doi.org/10.1016/S1470-2045(11)70393-X.

Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutation of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8. https://doi.org/10.1016/S1470-2045(09)70364-X.

Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomised phase 3 study. Lancet Oncol. 2011;12(8):735–42. https://doi.org/10.1016/S1470-2045(11)70184-X.

Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomised study. Ann Oncol. 2017;28(10):2443–50. https://doi.org/10.1093/annonc/mdx359.

Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutation. J Clin Oncol. 2013;31(27):3327–34. https://doi.org/10.1200/JCO.2012.44.2806.

Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutation advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25. https://doi.org/10.1056/NEJMoa1713137.

Lee CK, Wu YL, Ding PN, et al. Impact of specific epidermal growth factor receptor (EGFR) mutation and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutation lung cancer: a meta-analysis. J Clin Oncol. 2015;33(17):1958–65. http://doi.org/https://doi.org/10.1200/jco.2014.58.1736.

Goto K, Nishio M, Yamamoto N, et al. A prospective, phase III, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer. 2013;82(1):109–14. https://doi.org/10.1016/j.lungcan.2013.07.003.

Zhang Y, Sheng J, Kang S, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One. 2014;9(9):e107161. https://doi.org/10.1371/journal.pone.0107161.

Care KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006;66(16):8163–71. https://doi.org/10.1158/0008-5472.CAN-06-0453.

Rossi S, Toschi L, Finocchiaro G, et al. Impact of exon 19 deletion subtypes in EGFR-mutation metastatic non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors. Clin Lung Cancer. 2019;20(2):82–7. https://doi.org/10.1016/j.cllc.2018.10.009.

Su J, Zhong W, Zhang X, et al. Molecular characteristics and clinical outcomes of EGFR 19 indel subtypes to EGFR TKIs in NSCLC patients. Oncotarget. 2017;8(67):111246–257. https://doi.org/10.18632/oncotarget.22768.

Kuiper JL, Heideman DA, Thunnissen E, et al. Incidence of T790M mutation in(sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer. 2014;85(1):19–24. https://doi.org/10.1016/j.lungcan.2014.03.016.

Socinski MA, Villaruz LC, Ross J. Understanding mechanisms of resistance in the epithelial growth factor receptor in non-small cell lung cancer and the role of biopsy at progression. Oncologist. 2017;22(1):3–11. https://doi.org/10.1634/theoncologist.2016-0285.

Li W, Ren S, Li J, et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer. 2014;84(3):295–300. https://doi.org/10.1016/j.lungcan.2014.03.011.

Chung KP, Wu SG, Wu JY.et al. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res. 2012;18(12):3407–7. https://doi.org/10.1158/1078-0432.CCR-11-2353.

Kaneda T, Hata A, Tomioka H, et al. Possible different EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. Lung Cancer. 2014;86(2):213–8. https://doi.org/10.1016/j.lungcan.2014.09.014.

Zhou Q, et al. ARTEMIS (CTONG 1509): Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC. Ann Oncol. 2019;30(suppl_5):v602–60. https://doi.org/10.1093/annonc/mdz260.

Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. https://doi.org/10.1056/NEJMoa1913662.